Violation Tracker Individual Record
Company:Alexion Pharmaceuticals Inc.
Date:July 2, 2020
Offense Group:competition-related offenses
Primary Offense:Foreign Corrupt Practices Act
Secondary Offense:financial institution supervision failures
The SEC found that two Alexion subsidiaries made payments to foreign government officials to secure favorable treatment for Alexion's drug Soliris.
Level of Government:federal
Action Type:agency action
Agency:Securities and Exchange Commission
Civil or Criminal Case:civil
HQ Country of Parent:United Kingdom
Ownership Structure of Parent:publicly traded
Major Industry of Parent:pharmaceuticals
Specific Industry of Parent:pharmaceuticals
Source of Data:
Source Notes:If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.